Keyword: EuroBiotech Report
In this week's EuroBiotech Report, Novartis pens $2.1 billion buyout, Roche trims pipeline, AstraZeneca pulled into Brexit scrap and more.
In our EuroBiotech roundup this week, Lilly hits Adocia with patent suit, EMA delays Kiadis decision and UCB trial misses endpoint.
The deal caps off a whirlwind year for Endocyte, which licensed the cancer drug that caught Novartis’ eye for $12 million just 12 months ago.
The most advanced drug to get the chop is RG6125, an anti-cadherin 11 antibody that entered a phase 2 rheumatoid arthritis trial last year.
The trial linked the fixed-dose combination to a statistically significant improvement on a measure of patient disability.
Pro-Remain politicians saw the reiteration of an old position as evidence that the split from the U.K. will decimate life science research.
The appointment puts a CEO known for raising huge sums of cash in charge of a well-regarded bispecific antibody R&D shop.
The revised deal sets Roche up to work with SQZ on antigen-presenting cells designed to trigger killer T cell attacks against tumors.
In this week's EuroBiotech Report, EU funding is on track for new highs, Orchard plans a $173 million IPO, Sitryx raises $30 million and more.
In our EuroBiotech roundup this week, FDA hits Acacia with CRL, Therachon buys GLyPharma and Oryzon starts phase 2a trial.